Richard Tepper, MD
Infectious Disease · Southampton, PANPI 1588639165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $402 and has fallen 80.1% since, to $80 in 2025.
Across 62 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$287
- Johnson & Johnson$239
- Gilead$180
- Merck$167
- AbbVie$120
- Paratek Pharmaceuticals, Inc.$96
- plus $243 from 7 others
What the payments were for
- Speaking & faculty fees$212%
- Food & beverage$1,23393%
- Education$786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 9 | $287 |
| Johnson & Johnson | 10 | $239 |
| Gilead | 7 | $180 |
| Merck | 10 | $167 |
| AbbVie(2 entities) | 6 | $120 |
| Paratek Pharmaceuticals, Inc. | 5 | $96 |
| Viiv Healthcare Company | 5 | $68 |
| Vyera Pharmaceuticals, LLC | 2 | $41 |
| Astellas Pharma US Inc | 3 | $40 |
| Napo Pharmaceuticals Inc | 2 | $32 |
| Melinta Therapeutics, LLC | 1 | $24 |
| La Jolla Pharmaceutical Company | 1 | $22 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,332 in reported general payments places this provider in the 80th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 58 | $225,156 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 56 | $208,438 |
| NuzyraOmadacycline Tosylate | 13 | $178,155 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $78,275 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,778 |
| Daptomycin | 18 | $25,971 |
| AbacavirAbacavir Sulfate | 11 | $2,623 |
| CeftriaxoneCeftriaxone Sodium | 12 | $1,457 |
| Vancomycin Hcl | 15 | $1,434 |
| Ethambutol Hcl | 28 | $1,196 |
| Doxycycline Hyclate | 33 | $987 |
| Azithromycin | 43 | $725 |
| Rifampin | 15 | $715 |
| Gabapentin | 21 | $490 |
| Ciprofloxacin Hcl | 20 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $180 | $331,20884 claims |
| Viiv Healthcare CompanyTriumeq | $68 | $208,43856 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $96 | $178,15513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 infectious disease providers in Pennsylvania.
Other infectious disease in Southampton
- William PaceSouthampton$472K
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- David WuWest Chester$483K
- Amesh AdaljaPittsburgh$415K
- Brett GilbertWynnewood$352K
- Timothy BabinchakPhoenixville$311K
- Tuesdae Stainbrookdu Bois$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.